AI-Powered Digital Twins Revolutionize Lung Diagnostics and Surgical Planning
Berlin, Germany – L&T Technology Services (LTTS) has unveiled a groundbreaking artificial intelligence (AI)-powered digital twin platform designed to transform lung diagnostics, surgical planning, and navigation. The platform, leveraging the power of NVIDIA’s Physical AI infrastructure, promises to enhance precision and improve patient outcomes in the fight against lung disease. This innovation arrives at a critical time, as respiratory illnesses remain a leading cause of morbidity and mortality worldwide, and early, accurate diagnosis is paramount for effective treatment.
The new platform directly integrates with existing computed tomography (CT) imaging workflows, utilizing sophisticated deep learning models to reconstruct highly detailed, three-dimensional digital twins of individual patient lungs. This allows clinicians to move beyond static images and visualize the complex anatomy in an interactive and dynamic environment. The ability to simulate procedural pathways for bronchoscopy and biopsy planning represents a significant leap forward in pre-operative assessment and risk mitigation.
Building on NVIDIA’s Physical AI Infrastructure
At the heart of the LTTS platform lies NVIDIA’s advanced Physical AI infrastructure, a suite of technologies designed to accelerate and enhance AI-driven applications. NVIDIA Omniverse and OpenUSD are key components, enabling interactive 3D visualization and immersive exploration of intricate anatomical structures. This allows medical professionals to navigate the digital lung with unprecedented clarity, and detail. According to NVIDIA, Omniverse is designed for building and operating metaverse and 3D workflows, and OpenUSD is a universal scene description format.
Optimized AI inference performance is achieved through NVIDIA TensorRT, ensuring high-speed clinical workflows and rapid processing of complex data. NVIDIA MONAI, an open-source framework for AI-powered healthcare imaging, facilitates advanced segmentation, automatically identifying critical structures such as vessels, airways, lobes, and, crucially, tumors. This automated identification can significantly reduce the time required for analysis and improve the accuracy of diagnoses.
From Static Scans to Dynamic Simulations
The platform’s ability to convert static CT scans into dynamic, interactive models is a game-changer for clinicians. This transformation allows for a more thorough examination of anatomical structures, facilitating more precise surgical route planning and enhancing the accuracy of bronchoscopic procedures. The framework supports a comprehensive range of functionalities, including volumetric analysis, automated segmentation, advanced visualization, and sophisticated navigation path planning – all designed to improve pre-operative planning efficiency and bolster procedural safety.
Amit Chadha, CEO and Managing Director of L&T Technology, emphasized the transformative potential of the platform. “By combining LTTS’ engineering expertise in medical imaging and digital health platforms with the power of Nvidia’s Physical AI infrastructure, we are enabling a new generation of AI-powered biological digital twins for precision medicine,” Chadha stated. “These platforms can transform how clinicians visualise lung anatomy, plan interventions, and deliver precision care. The impact will be visible across the global healthcare ecosystem in the years ahead.”
Digital Twins: A Growing Trend in Precision Medicine
The emergence of digital twins as a powerful tool in precision medicine is gaining momentum. David Niewolny, Head of Healthcare and Medical Technology Business Development at NVIDIA, highlighted the significance of this trend. “Digital twins are emerging as a powerful new tool for precision medicine,” Niewolny explained. “By leveraging Nvidia Physical AI infrastructure, Omniverse, MONAI and TensorRT, LTTS is transforming CT data into interactive lung digital twins that allow clinicians to visualise anatomy in 3D, simulate procedures and plan clinical interventions with greater confidence.”
This development aligns with a broader trend of leveraging AI and machine learning to improve healthcare outcomes. Earlier in March 2026, Droplet Biosciences reported a reduction in genomic analysis turnaround time for residual cancer detection by adopting graphics processing unit (GPU)-accelerated workflows using NVIDIA Parabricks software, as reported by Medical Device Network. This demonstrates the growing adoption of NVIDIA technologies within the medical field to accelerate and enhance diagnostic capabilities.
Implications for Lung Cancer and Respiratory Disease Management
The potential applications of this AI-powered digital twin platform extend across a wide spectrum of lung conditions, including lung cancer, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases. For lung cancer, the platform could facilitate earlier and more accurate tumor detection, enabling more effective treatment strategies. In the context of COPD, the platform could help clinicians better understand the progression of the disease and personalize treatment plans based on individual patient anatomy and physiology.
The ability to simulate procedures before they are performed also holds significant promise for reducing surgical risks and improving patient safety. By virtually “walking through” a bronchoscopy or biopsy, surgeons can identify potential challenges and optimize their approach, minimizing the likelihood of complications. This is particularly significant in complex cases where anatomical variations or the presence of tumors can make procedures more challenging.
Looking Ahead: The Future of AI in Pulmonary Medicine
The launch of this platform by L&T Technology represents a significant step forward in the application of AI to pulmonary medicine. As AI technology continues to evolve, People can expect to see even more sophisticated tools emerge that will further enhance our ability to diagnose, treat, and prevent lung diseases. The integration of digital twins with other emerging technologies, such as augmented reality and virtual reality, could create even more immersive and interactive training environments for medical professionals.
The development and deployment of these technologies will require ongoing collaboration between engineers, clinicians, and researchers. Addressing ethical considerations, such as data privacy and algorithmic bias, will also be crucial to ensure that these tools are used responsibly and equitably. The future of pulmonary medicine is undoubtedly intertwined with the continued advancement of AI and the power of digital twins.
L&T Technology has not yet announced specific timelines for wider clinical implementation or regulatory approvals. Further updates on the platform’s availability and performance will be closely watched by the medical community. Readers interested in learning more about the platform are encouraged to visit the L&T Technology Services website for the latest information.
What are your thoughts on the potential of AI-powered digital twins in healthcare? Share your comments below.